Celgene

Juno Therapeutics is a biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute. The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. The company raised $300 million through private funding and a further $265 million through their IPO. On January 22, 2018 Juno Therapeutics was acquired by Celgene for $9 billion.

Juno Therapeutics

Lenalidomide (trade name Revlimid) is a derivative of thalidomide introduced in 2004.  It was initially intended as a treatment for multiple myeloma, for which thalidomide is an accepted therapeutic treatment. Lenalidomide has also shown efficacy in the class of hematological disorders known as myelodysplastic syndromes (MDS). Along with several other drugs developed in recent years, lenalidomide has significantly improved overall survival in myeloma (which formerly carried a poor prognosis), although toxicity remains an issue for users. It costs $163,381 per year for the average patient.

Revlimid

Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases in patients with limited treatment options.   There are hundreds of clinical trials at major medical centers evaluating compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), pancreatic cancer, non-small lung cancer and melanoma.   In addition, several compounds are being evaluated as therapies for serious inflammatory diseases such as psoriasis and psoriatic arthritis.

Celgene (CELG) closed at $94.09 in the latest trading session, marking a -0.96% move from the prior day.

Celgene (CELG) Dips More Than Broader Markets: What You Should Know

Acceleron Pharma

Celgene and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.

Celgene & Acceleron Submit BLA for Luspatercept to the FDA

The company has also been able to file an application for regulatory approval for the European Union for Ozanimod to treat patients with relapsing multiple sclerosis.

The Refiling Of The NDA For Celgene Is A Major Step Forward Toward 2 Potential Approvals

Shareholder support for its proposed merger with Bristol-Myers appears back on track.

Why Celgene's Shares Soared 13.5% in March

Celgene receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.

Celgene Gets Positive CHMP Nod for Revlimid Label Expansion

A series of analysts downgraded Celgene stock Monday after it looked likely Bristol-Myers's $74 billion acquisition of it would succeed. The next key step is an April 12 shareholder vote.

Celgene Remains In Buy Zone As Bristol Likely To Clinch Takeover

Bristol-Myers

Bristol-Myers' acquisition offer for Celgene likely to get majority of shareholders' vote following support from Institutional Shareholder Services and Glass Lewis.

Bristol-Myers' Acquisition of Celgene Looks Certain

Analysts at UBS downgraded shares of Celgene Corp.  on Monday to neutral from buy, but raised their stock price target to $102 from $94.

Celgene stock downgraded to neutral at UBS

CELG appears to be about to become a BMY asset, based on end-of-week news flow.

Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS

Activist investor Starboard Value has ended its fight against Bristol-Myers Squibb’s buyout of biotechnology company Celgene after two prominent proxy advisors announced their support for the deal earlier on Friday.

Activist Starboard drops out of Celgene fight as proxy firms back Bristol-Myers bid

Shares of Celgene Corp. shot up 7.5% in very active midday trade Friday, after activist investors Starboard Value LP said it would no longer oppose the Bristol-Myers Squibb Co.

Celgene's stock surges, after Starboard withdraws proxy fight of Bristol-Myers buyout deal

Celgene stock popped in early trading Friday on reports the Institutional Shareholder Services voted in favor of Bristol-Myers Squibb's looming acquisition of the biotechnology giant.

Celgene Jumps On Reports Proxy Vote Favors Bristol's Takeover

Institutional Shareholder Services recommends Bristol-Myers Squibb shareholders vote in favor of its bid to buy Celgene.

Celgene shares pop after top proxy advisor ISS recommends Bristol-Myers investors approve buyout bid

Vertex Pharmaceuticals

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Celgene and Vertex Pharmaceuticals. But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

Celgene and Vertex Pharmaceuticals ?

AbbVie

DaVita

These stocks are dirt cheap. But perhaps not for too much longer.

Bargain Stocks You Can Buy Today

This mega-merger could be on the rocks following objections by high-profile investors.

Is Celgene and Bristol-Myers a Match Made in Heaven or Doomed to Fail?

Bristol-Myers Squibb's acquisition of Celgene received a boost Thursday after U.S. patent officials rejected a claim against Celgene's blockbuster cancer treatment Revlimid, an analyst said.

Key Celgene Issue That Could 'Unnerve' Bristol Takeover Was Just Tossed

Teva Pharmaceutical

Walgreens

These healthcare giants are taking the word "value" to an extreme.

3 Brand-Name Healthcare Stocks That Haven't Been This Cheap in a Decade

Galapagos

Zealand Pharma

These three healthcare gems have the full attention of our team of experts.

3  Top Biotech Stocks to Buy in March

Apple

Balchem

Gilead Sciences

Alphabet

Find out which stocks have performed the best over the past 20 years, which industries generated the most growth, and how much these stocks appreciated.

News for Celgene Stock (CELG)